COST-UTILITY ANALYSIS OF LURASIDONE FOR THE TREATMENT OF SCHIZOPHRENIA IN CHINA

被引：0
|
作者：
Cao, D. [1 ]
Liu, J. [1 ,2 ]
Liu, J. [1 ,2 ]
He, X. [1 ]
Wu, J. [1 ]
机构：
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin, Peoples R China
[2] Sumitomo Pharma Suzhou Co Ltd, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH33
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [1] Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
    Liu, Jia
    Cao, Lidan
    Wu, Jing
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [2] Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
    Rajagopalan, Krithika
    Trueman, David
    Crowe, Lydia
    Squirrell, Daniel
    Loebel, Antony
    PHARMACOECONOMICS, 2016, 34 (07) : 709 - 721
  • [3] Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
    Krithika Rajagopalan
    David Trueman
    Lydia Crowe
    Daniel Squirrell
    Antony Loebel
    PharmacoEconomics, 2016, 34 : 709 - 721
  • [4] Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China (vol 9, 987408, 2022)
    Liu, Jia
    Cao, Lidan
    Wu, Jing
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [5] Cost-utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia in Scotland
    Rajagopalan, K.
    Crowe, L.
    Trueman, D.
    Pikalov, A.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2015, 30
  • [6] Cost-utility analysis in schizophrenia
    Awad, AG
    Voruganti, LP
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 22 - 28
  • [7] A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
    Abdall-Razak, Ali
    Macaulay, Alex
    Tiefenbach, Jakov
    Borges, Karen
    Mathema, Sina
    Zuberi, Sameer
    HELIYON, 2019, 5 (09)
  • [8] Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
    Luo, Rui
    Lu, He
    Li, Hengfen
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] COST-UTILITY OF LURASIDONE VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH SCHIZOPHRENIA IN ITALY
    Bini, C.
    Marcellusi, A.
    Rotundo, M.
    D'ambrosio, F.
    Mennini, F. S.
    VALUE IN HEALTH, 2019, 22 : S686 - S686
  • [10] COST-UTILITY AND BUDGET IMPACT ANALYSES COMPARING LURASIDONE WITH ARIPIPRAZOLE IN ADULTS WITH SCHIZOPHRENIA IN SCOTLAND
    Rajagopalan, K.
    Trueman, D.
    Crowe, L.
    Patel, P.
    Loebel, A.
    VALUE IN HEALTH, 2015, 18 (07) : A408 - A409
12345